financetom
Business
financetom
/
Business
/
Media company AMC Networks beats Q2 revenue, profit estimates on price hikes, subscriber growth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Media company AMC Networks beats Q2 revenue, profit estimates on price hikes, subscriber growth
Aug 8, 2025 4:26 AM

Overview

* AMC Networks ( AMCX ) Q2 revenue falls 4% but beats analyst expectations

* Adjusted EPS of $0.69 beats estimates, driven by streaming growth

* Co reduces gross debt by $400 mln through financing transactions

Outlook

* AMC Networks ( AMCX ) expects $250 mln free cash flow for 2025

* Company sees streaming revenue growth accelerating

* AMC Networks ( AMCX ) highlights strength in content licensing

Result Drivers

* STREAMING REVENUE - Streaming revenues grew 12% due to price increases and subscriber growth

* CONTENT LICENSING - Content licensing revenues rose 26% due to timing and availability of deliveries

* ADVERTISING DECLINE - Advertising revenues fell 18% due to linear ratings declines and lower marketplace pricing

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $600.02 $582 mln

Revenue mln (5

Analysts

)

Q2 Beat $0.69 $0.61 (6

Adjusted Analysts

EPS )

Q2 EPS $0.91

Q2 Beat $109.39 $71.70

Adjusted mln mln (5

Operatin Analysts

g Income )

Q2 EBIT $64.47

mln

Q2 Free $95.74

Cash mln

Flow

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 4 "sell" or "strong sell"

* The average consensus recommendation for the broadcasting peer group is "buy."

* Wall Street's median 12-month price target for AMC Networks Inc ( AMCX ) is $6.00, about 0% even its August 7 closing price of $6.00

* The stock recently traded at 2 times the next 12-month earnings vs. a P/E of 2 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
RB Global Outperform Rating Confirmed at Barrington Research Ahead of Q3 Results
RB Global Outperform Rating Confirmed at Barrington Research Ahead of Q3 Results
Nov 3, 2025
11:27 AM EST, 11/03/2025 (MT Newswires) -- RB Global ( RBA ) had its outperform rating and its target range of $120-130 maintained at Barrington Research ahead of the company's third quarter financial results. The brokerage expects Gross Transaction Value (GTV) of $3.69 billion, revenue of $1.04 billion, and adjusted EBITDA of $303 million in Q3 and said consensus expectations...
Canada says it is launching dispute settlement proceedings against Stellantis
Canada says it is launching dispute settlement proceedings against Stellantis
Nov 3, 2025
OTTAWA, Nov 3 (Reuters) - Canada is launching dispute settlement proceedings against auto manufacturer Stellantis ( STLA ) over its decision to shift production from a Canadian plant to one in the United States, Industry Minister Melanie Joly said on Monday. Stellantis ( STLA ) said last month it would to move its Jeep Compass production from Ontario to the...
Colgate-Palmolive Likely to See Organic Sales Growth Improvement, Morgan Stanley Says
Colgate-Palmolive Likely to See Organic Sales Growth Improvement, Morgan Stanley Says
Nov 3, 2025
11:26 AM EST, 11/03/2025 (MT Newswires) -- Colgate-Palmolive's ( CL ) Q3 results indicated a soft quarter but the company will likely start seeing an improvement from here in organic sales growth as comparisons ease and temporary pressure points from Q3 dissipate, Morgan Stanley said in a note emailed Monday. The investment firm said that Colgate's Q3 results showed it...
US FDA's drug division chief resigns amid ethics concerns and lawsuit
US FDA's drug division chief resigns amid ethics concerns and lawsuit
Nov 3, 2025
(Reuters) -The director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, George Tidmarsh, resigned on Sunday amid serious concerns about his personal conduct, a Department of Health and Human Services spokesperson told Reuters on Monday. He was placed on administrative leave on Friday after the Office of the General Counsel and the Office of the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved